ArticleResearch square2025

Efficacy of the GLP-1 receptor agonist, semaglutide, in abstinence from illicit and nonprescribed opioids in an outpatient population with treatment-refractory OUD: A randomized, double-blind, placebo-controlled clinical trial protocol.

Christopher S Freet et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.